DongKoo Bio & Pharma, a Korean company known for its dermatological products, has announced a strategic investment of 10 billion won ($7.2 million) into Qurient, a local biotech, becoming its largest shareholder.Through this latest investment, DongKoo will acquire approximately 2.56 million new shar
Handok said it finalized an exclusive distribution and supply agreement with Nxera Pharma Korea, the offshoot of a Japan-based pharmaceutical company Nxera, for Pivlaz, a drug designed to prevent cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysm
Pharmaceutical products are difficult to develop, manufacture, and produce, as they are directly linked to human lives. Moreover, the importance of drug distribution management has been emphasized recently. That’s because, unlike in the past, when synthetic chemical drugs were the mainstay, biologic
Yuyu Pharma said its contract manufacturing organization (CMO) business, a new growth engine, is on a roll with a series of contract signings.This month, the company signed new CMO agreements with 10 pharmaceutical companies for manufacturing Fexogien Tab. (fexofenadine hydrochloride), an antihistam
OliX Pharmaceuticals, a Korean biotech firm specializing in RNA interference technologies, recently announced the promising results of its hair loss treatment, OLX104C, at the 13th World Congress for Hair Research (WCHR 2024) held in Texas, the U.S. from April 6-9.The WCHR, hosted by the Internation
PharmaEssentia Korea said it hosted a myeloproliferative neoplasms (MPN) forum to share the latest insights on Besremi (ropeginterferon alfa-2b), a treatment for polycythemia vera (PV) on Thursday last week.The forum featured two world-renowned experts in the field of MPN -- Professor Hans Carl Hass
Janssen's Rybrevant (amivantamab), a treatment for EGFR exon20 insertion non-small cell lung cancer (NSCLC), a rare form of lung cancer with a poor prognosis, is making its third attempt to get reimbursement in Korea.The drug’s third challenge for insurance coverage comes when the “nominality” of th
NKMAX, a local biotech firm specializing in NK cell therapy, announced plans to file an objection to its potential delisting from the Korea Exchange (KRX).The company, which has been listed on the Kosdaq since August 2018, is facing delisting due to significant operational challenges.On March 5, NKM
GSK's Shingrix, the world's only shingles vaccine that can be given to immunocompromised individuals such as cancer patients, is notorious for causing pain, unlike any other vaccine, from the moment it is given to three to four days afterward.So why is it so painful to receive Shingrix, a recombinan
AbbVie Korea's psoriatic disease treatment Skyrizi (risankizumab) won approval from the Ministry of Food and Drug Safety (MFDS) on Tuesday for treating moderate-to-severe pustular psoriasis of the hands and feet in adults (18 years and older) who have had an inadequate response to or are intolerant
Recent advancements in HIV treatment and prevention, including the roll-out of pre-exposure prophylaxis (PrEP) and the bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) treatment regimen, have highlighted the critical need for ethnic-centered approaches in healthcare.Therefore, understanding
GI Innovation is accelerating the development of a subcutaneous (SC) formulation of its immuno-oncology candidate GI-102.The company said Tuesday that it has applied for approval to change the IND (investigational new drug) application for the GI-102 phase 1/2a clinical trial to the Ministry of Food
Saruparib, a next-generation PARP inhibitor in development by AstraZeneca, has garnered attention from cancer experts worldwide after showing clinical benefit in patients with homologous recombination repair-deficient (HRD) breast cancer.However, it is questionable whether Korean patients who face s
Curocell, a local chimeric antigen receptor-T (CAR-T) developer, said it will start developing a next-generation Anti-CD19 CAR-T therapy for treatment-resistant systemic lupus erythematosus (SLE) as part of the2024 Multi-Ministerial Regenerative Medicine Technology Development Program.This initiativ
Hugel, a total medical aesthetics company, said Tuesday that its polydioxanone (PDO) suture brand Licellvi (domestic product name: Blue Rose Forte) has received a product license from the Brazilian National Agency for Food and Drug Surveillance (ANVISA).Licellvi is a PDO suture brand of JWorld, a su
An increasing number of health supplements are differentiating themselves from traditional forms, such as capsules and pills, to various formulations, attempting to attract consumers with formulations that focus on portability and convenience of consumption.CJ ENM's digital marketing affiliate, Mezz
Daewoong Pharmaceutical said that it applied for product approval for Envlo, the first homegrown sodium-glucose cotransporter 2 (SGLT2) diabetes drug in Korea and the nation's 36th newly developed drug, to Mexico's Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS).COFEPRIS is
Celltrion said it has completed a registration contract for its subcutaneous (SC) Remicade biosimilar, Zymfentra (infliximab), with one of the top three pharmaceutical benefit managers (PBMs) in the United States."We are pleased to announce through our website that we have successfully closed a deal
EuBiologics, a Korean vaccine maker targeting the global public health market, said it opened a new office at the Cambridge Innovation Center (CIC) in Boston, one of the largest biotech clusters in the world.EuBiologics' new office opening comes after their selection by KHIDI (Korea Health Industry
In a move signaling a potential resolution to ongoing family disputes, Hanmi Science, the holding company of Hanmi Pharm, announced the appointment of Lim Jong-hoon as co-CEO alongside the current chairperson, Song Young-sook.The decision came during a board meeting held at Hanmi headquarters in Son